Elizabeth R Plimack

List of Publications by Year
in descending order

175 papers	31,736 citations	17440 63 h-index	4991 167 g-index
178 all docs	178 docs citations	178 times ranked	27414 citing authors

#	Article	IF	Citations
1	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2015, 373, 1803-1813.	27.0	4,889
2	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2018, 378, 1277-1290.	27.0	3,334
3	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2019, 380, 1116-1127.	27.0	2,319
4	Pan-tumor genomic biomarkers for PD-1 checkpoint blockadeâ€“based immunotherapy. Science, 2018, 362, .	12.6	1,575
5	Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2017, 18, 312-322.	10.7	1,388
6	Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy. Cancer Cell, 2014, 25, 152-165.	16.8	1,358
7	First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncology, The, 2017, 18, 1483-1492.	10.7	1,034
8	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 479-505.	4.9	943
9	Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. Journal of Clinical Oncology, 2015, 33, 1430-1437.	1.6	914
10	Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. Journal of Clinical Oncology, 2018, 36, 1080-1087.	1.6	702
11	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1370-1385.	10.7	594
12	Prostate Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 19-30.	4.9	544
13	Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2020, 21, 1563-1573.	10.7	466
14	Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 804-834.	4.9	443
15	Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. European Urology, 2015, 68, 959-967.	1.9	395
16	Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. Journal of Clinical Oncology, 2017, 35, 3851-3858.	1.6	384
17	Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 329-354.	4.9	383
18	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open, 2020, 5, e001079.	4.5	343

#	Article	IF	Citations
19	Bladder Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 446-475.	4.9	309
20	Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncology, The, 2017, 18, 212-220.	10.7	307
21	Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncology, The, 2018, 19, 405-415.	10.7	305
22	Prostate Cancer, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 686-718.	4.9	294
23	Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 71-90.	4.9	248
24	Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity. Journal of Clinical Oncology, 2014, 32, 1895-1901.	1.6	241
25	Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2016, 22, 5461-5471.	7.0	234
26	Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treatment Reviews, 2017, 58, 70-76.	7.7	228
27	Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1240-1267.	4.9	220
28	Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. European Urology, 2017, 72, 368-376.	1.9	209
29	Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1081-1087.	4.9	208
30	Clinical Validation of Chemotherapy Response BiomarkerERCC2in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncology, 2016, 2, 1094.	7.1	205
31	Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with longâ€term followâ€up of the randomized, openâ€label, phase 3 CheckMate 025 trial. Cancer, 2020, 126, 4156-4167.	4.1	201
32	Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncology, The, 2016, 17, 1317-1324.	10.7	200
33	CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. European Urology, 2017, 72, 962-971.	1.9	199
34	Kidney Cancer, Version 3.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 151-159.	4.9	198
35	Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. Journal of Clinical Oncology, 2020, 38, 2658-2666.	1.6	186
36	NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1278-1285.	4.9	185

#	Article	IF	Citations
37	NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1041-1053.	4.9	171
38	NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1160-1170.	4.9	163
39	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. , 2020, 8, e000891.		160
40	Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression. JAMA Oncology, 2016, 2, 1179.	7.1	154
41	Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2014, 32, 5010-5010.	1.6	154
42	Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. , 2018, 6, 109.		151
43	Inhibition of hypoxia-inducible factor-2Î± in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nature Medicine, 2021, 27, 802-805.	30.7	151
44	Penile Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 594-615.	4.9	149
45	Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. Journal of Clinical Oncology, 2017, 35, 2993-3001.	1.6	145
46	A Phase 2 Trial of Sunitinib in Patients with Advanced Nonâ€“clear Cell Renal Cell Carcinoma. European Urology, 2012, 62, 1013-1019.	1.9	139
47	PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection. Cancer Immunology Research, 2014, 2, 320-331.	3.4	138
48	Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncology, The, 2019, 20, 581-590.	10.7	124
49	Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma. Journal of Clinical Oncology, 2012, 30, 3545-3551.	1.6	115
50	Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. Oncologist, 2017, 22, 1232-1237.	3.7	109
51	ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2019, 25, 977-988.	7.0	104
52	Conditional survival and longâ€term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer, 2022, 128, 2085-2097.	4.1	103
53	Decitabine and its role in the treatment of hematopoietic malignancies. Leukemia and Lymphoma, 2007, 48, 1472-1481.	1.3	101
54	Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nature Communications, 2017, 8, 2193.	12.8	99

#	Article	IF	Citations
55	Testicular Cancer, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 772-799.	4.9	98
56	AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors. Oncologist, 2013, 18, 819-820.	3.7	96
57	Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. European Urology, 2019, 76, 599-603.	1.9	95
58	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1213-1224.	4.9	93
59	Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer. Journal of Oncology Practice, 2016, 12, e755-e764.	2.5	83
60	Prostate Cancer, Version 1.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1471-1479.	4.9	82
61	A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma. Journal of Urology, 2015, 194, 297-303.	0.4	80
62	Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. Journal of Urology, 2020, 203, 690-698.	0.4	76
63	Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. Journal of Clinical Oncology, 2018, 36, 376-382.	1.6	75
64	Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 1088-1095.	1.6	72
65	Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU International, 2017, 120, 782-792.	2.5	68
66	Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012.. Journal of Clinical Oncology, 2015, 33, 4502-4502.	1.6	64
67	Baseline Renal Function Status Limits Patient Eligibility to Receive Perioperative Chemotherapy for Invasive Bladder Cancer and Is Minimally Affected by Radical Cystectomy. Urology, 2011, 77, 160-165.	1.0	63
68	A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157. Clinical Cancer Research, 2017, 23, 3003-3011.	7.0	59
69	Kidney Cancer, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 175-182.	4.9	56
70	Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology Oncology, 2020, 3, 544-547.	5.4	52
71	Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2014, 20, 4747-4757.	7.0	50
72	Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors. Investigational New Drugs, 2015, 33, 1040-1047.	2.6	50

#	Article	IF	Citations
73	Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.. Journal of Clinical Oncology, 2020, 38, 5001-5001.	1.6	50
74	Coexisting Hybrid Malignancy in a Solitary Sporadic Solid Benign Renal Mass: Implications for Treating Patients Following Renal Biopsy. Journal of Urology, 2014, 191, 296-300.	0.4	49
75	Approved checkpoint inhibitors in bladder cancer: which drug should be used when?. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591878831.	3.2	49
76	Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).. Journal of Clinical Oncology, 2017, 35, 4502-4502.	1.6	49
77	Micropapillary bladder cancer: Current treatment patterns and review of the literature. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 826-832.	1.6	48
78	Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions. Current Urology Reports, 2018, 19, 109.	2.2	47
79	Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU International, 2011, 107, 58-62.	2.5	46
80	Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma. Current Treatment Options in Oncology, 2017, 18, 7.	3.0	46
81	Emerging role of immunotherapy in urothelial carcinomaâ€"Advanced disease. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 538-547.	1.6	41
82	Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis. European Urology, 2018, 74, 387-393.	1.9	41
83	First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer. Oncologist, 2019, 24, e930-e942.	3.7	41
84	Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). Journal of Clinical Oncology, 2022, 40, 2913-2923.	1.6	40
85	Distress and Financial Distress in Adults With Cancer: An Age-Based Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1224-1233.	4.9	38
86	Targeting Signaling Transduction Pathways in Bladder Cancer. Current Oncology Reports, 2015, 17, 58.	4.0	37
87	Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).. Journal of Clinical Oncology, 2018, 36, 4524-4524.	1.6	36
88	Muscle-invasive urothelial bladder cancer: an update on systemic therapy. Therapeutic Advances in Urology, 2015, 7, 312-330.	2.0	34
89	Recent developments in the treatment of advanced bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 109-114.	1.6	34
90	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. European Urology, 2022, 81, 266-271.	1.9	33

#	Article	IF	Citations
91	Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma. Cancer Medicine, 2016, 5, 192-199.	2.8	32
92	Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscleâ€invasive bladder cancer. Cancer, 2019, 125, 3155-3163.	4.1	32
93	Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107. Kidney Cancer, 2017, 1, 123-132.	0.4	31
94	Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status. European Urology Oncology, 2020, 3, 351-359.	5.4	31
95	Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon. Cancer, 2009, 115, 1859-1866.	4.1	30
96	Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy. BJU International, 2015, 116, 351-357.	2.5	29
97	Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy. European Urology Oncology, 2021, 4, 170-179.	5.4	28
98	Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database. Frontiers in Oncology, 2018, 8, 463.	2.8	27
99	Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial. European Urology Oncology, 2018, 1, 54-60.	5.4	26
100	Role of Checkpoint Inhibition in Localized Bladder Cancer. European Urology Oncology, 2018, 1, 190-198.	5.4	26
101	Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). Journal of Clinical Oncology, 2021, 39, 2486-2496.	1.6	26
102	Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies. European Urology Oncology, 2019, 2, 355-364.	5.4	25
103	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. Clinical Cancer Research, 2021, 27, 6687-6695.	7.0	25
104	Optimizing Systemic Therapy for Bladder Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 793-804.	4.9	23
105	Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with modern treatment techniques. Practical Radiation Oncology, 2015, 5, e215-e222.	2.1	21
106	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. Clinical Cancer Research, 2022, 28, 2050-2060.	7.0	21
107	A Phase I Study of Temsirolimus and Bryostatinâ€1 in Patients With Metastatic Renal Cell Carcinoma and Soft Tissue Sarcoma. Oncologist, 2014, 19, 354-355.	3.7	20
108	Clinical implications of molecular subtyping in bladder cancer. Current Opinion in Urology, 2019, 29, 350-356.	1.8	20

#	Article	IF	Citations
109	The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. Clinical Cancer Research, 2017, 23, 3557-3565.	7.0	19
110	Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer. Clinical Cancer Research, 2021, 27, 2011-2022.	7.0	19
111	KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)â€" Updated response and survival results.. Journal of Clinical Oncology, 2019, 37, 4546-4546.	1.6	19
112	Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review. Clinical Genitourinary Cancer, 2017, 15, e337-e343.	1.9	18
113	Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer. Bladder Cancer, 2018, 4, 9-18.	0.4	18
114	A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma. Cancer, 2019, 125, 2400-2408.	4.1	18
115	Biweekly 72-Hour 9-Aminocamptothecin Infusion As Second-Line Therapy for Ovarian Carcinoma: Phase II Study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 2004, 22, 120-126.	1.6	17
116	Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial. European Journal of Cancer, 2021, 145, 1-10.	2.8	17
117	Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials. Discovery Medicine, 2014, 18, 341-50.	0.5	17
118	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. , 2021, 9, e002552.		16
119	Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. European Urology, 2019, 76, 425-429.	1.9	15
120	Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer. Oncologist, 2019, 24, 688-690.	3.7	15
121	Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial. European Urology Oncology, 2020, 3, 717-724.	5.4	15
122	Molecular Profiling of Exceptional Responders to Cancer Therapy. Oncologist, 2021, 26, 186-195.	3.7	15
123	Potential role of 124I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics: Targets and Therapy, 2012, 6, 395.	3.2	14
124	Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. Clinical Cancer Research, 2020, 26, 5598-5608.	7.0	13
125	A phase I study of decitabine with pegylated interferon Î±-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations. Investigational New Drugs, 2014, 32, 969-975.	2.6	12
126	Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. Clinical Genitourinary Cancer, 2018, 16, e483-e490.	1.9	12

#	Article	IF	Citations
127	A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1). Prostate Cancer and Prostatic Diseases, 2022, 25, 735-740.	3.9	12
128	Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2â€“4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. European Urology Oncology, 2019, 2, 248-256.	5.4	11
129	Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. European Urology Oncology, 2020, 3, 671-679.	5.4	11
130	Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer. JAMA Oncology, 2020, 6, 133.	7.1	11
131	Assessing Contemporary Trends in Female Speakership within Urologic Oncology. Urology, 2021, 150, 41-46.	1.0	11
132	Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pT0 Bladder Cancer: A Prospective Trial. Journal of Urology, 2021, 205, 1605-1611.	0.4	11
133	The European Urology Commitment to Gender Equity and Diversity: Expanding Cognitive Diversity through Inclusivity at the Podium. European Urology, 2021, 80, 450-453.	1.9	11
134	Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: An NYGOG and ECOG study. Gynecologic Oncology, 2006, 100, 324-329.	1.4	10
135	The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. Oncologist, 2019, 24, 1348-1355.	3.7	10
136	Provider and patient burdens of obtaining oral anticancer medications. American Journal of Managed Care, 2018, 24, e128-e133.	1.1	10
137	Selecting Targeted Therapies for Patients With Renal Cell Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 997-1006.	4.9	9
138	Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 811-822.	4.9	9
139	Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. European Urology, 2021, , .	1.9	9
140	TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy. Oncotarget, 2016, 7, 68206-68228.	1.8	8
141	Targeted Therapy for Metastatic Urothelial Cancer: A Work in Progress. Journal of Clinical Oncology, 2016, 34, 2088-2092.	1.6	8
142	Circulating biomarkers to guide systemic therapy for urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 502-509.	1.6	8
143	Integrating Immunotherapy Into the Management of Renal Cell Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 841-847.	4.9	8
144	Integration of Immunotherapy Into the Treatment of Advanced Urothelial Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 355-361.	4.9	8

#	Article	IF	Citations
145	Clinical Stage T1 Micropapillary Urothelial Carcinoma Presenting With Metastasis to the Pancreas. Urology, 2012, 79, e9-e10.	1.0	7
146	A Review of Interventional Clinical Trials in Renal Cell Carcinoma: A Status Report From the ClinicalTrials.gov WebSite. Clinical Genitourinary Cancer, 2015, 13, 142-149.	1.9	7
147	Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions. Immunotherapy, 2016, 8, 785-798.	2.0	7
148	Biomarkers for neoadjuvant checkpoint blockade response in urothelial cancer. Nature Medicine, 2019, 25, 1650-1651.	30.7	7
149	National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. Journal of Clinical Oncology, 2016, 34, 3346-3348.	1.6	6
150	Systemic therapy for bladder cancer finally comes into a new age. Future Oncology, 2016, 12, 2227-2242.	2.4	6
151	Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop. Nature Reviews Urology, 2021, , .	3.8	6
152	A Seat at the Table: The Correlation Between Female Authorship and Urology Journal Editorial Board Membership. European Urology Focus, 2022, 8, 1751-1757.	3.1	6
153	A Wealth of New Options: A Case Presentation of the Management of Castration-Recurrent Prostate Cancer. Seminars in Oncology, 2012, 39, 1-8.	2.2	5
154	Second-generation Androgen Receptorâ€“targeted Therapies in Nonmetastatic Castration-resistant Prostate Cancer: Effective Early Intervention or Intervening Too Early?. European Urology, 2016, 70, 971-973.	1.9	5
155	Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. Clinical Genitourinary Cancer, 2016, 14, 511-517.	1.9	5
156	Systemic Therapy for Advanced Nonâ€“clear-Cell Renal Cell Carcinoma: Slow but Definite Progress. European Urology, 2021, 80, 171-173.	1.9	5
157	Corticosteroids and Prostate Cancer: Friend or Foe?. European Urology, 2015, 67, 874-875.	1.9	4
158	Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy Regimens. Clinical Genitourinary Cancer, 2021, 19, 125-134.	1.9	4
159	Role of immunotherapy in localized muscle invasive urothelial cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 17588359211045858.	3.2	4
160	Evolving landscape of the treatment of metastatic clear cell renal cell carcinoma. Clinical Advances in Hematology and Oncology, 2018, 16, 677-686.	0.3	4
161	First-line Immunotherapy in Metastatic Urothelial Carcinoma. European Urology Focus, 2020, 6, 45-47.	3.1	3
162	Measuring the Efficacy and Value of Urothelial Cancer Urinary Biomarkers. Annals of Internal Medicine, 2015, 163, 954-955.	3.9	2

#	Article	IF	Citations
163	Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?. Annals of Translational Medicine, 2019, 7, S95-S95.	1.7	2
164	Association between baseline body mass index and survival in men with metastatic hormoneâ€sensitive prostate cancer: ECOGâ€ACRIN CHAARTED E3805. Prostate, 2022, 82, 1176-1185.	2.3	2
165	Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. Journal of Clinical Oncology, 2014, 32, 4171-4172.	1.6	1
166	Immunotherapy for metastatic urothelial carcinoma: putting the brakes on releasing the brake. Immunotherapy, 2018, 10, 423-425.	2.0	1
167	Safety of neoadjuvant chemotherapy in patients with muscleâ€invasive bladder cancer and malignant ureteric obstruction. BJU International, 2021, , .	2.5	1
168	Prolonged natural progression from localized to symptomatic renal cell carcinoma. Canadian Journal of Urology, 2012, 19, 6578-80.	0.0	1
169	Reply to S. Buti and S. Culine. Journal of Clinical Oncology, 2013, 31, 1615-1616.	1.6	0
170	Osteoclast Inhibitors in Advanced Prostate Cancer: Does the Benefit Extend Beyond Skeletal-Related Events?. European Urology, 2015, 68, 578-580.	1.9	0
171	Fox Chase Cancer Center's Genitourinary Division: a national resource for research, innovation and patient care. Future Oncology, 2016, 12, 887-891.	2.4	0
172	Bending the Curve of Advanced Urothelial Carcinoma. Journal of Oncology Practice, 2017, 13, 319-320.	2.5	0
173	Chemoimmunotherapy in Metastatic Urothelial Carcinoma. European Urology, 2018, 73, 760-762.	1.9	0
174	Reply by Authors. Journal of Urology, 2020, 203, 697-698.	0.4	0
175	Placing Adjuvant Chemotherapy in the Evolving Paradigm of Perioperative Therapy for Bladder Cancer. European Urology, 2022, 81, 62-63.	1.9	0